

HR 1776

Improving Access To Affordable Prescription Drugs Act

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Mar 29, 2017

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Apr 5, 2017)

Official Text: <https://www.congress.gov/bill/115th-congress/house-bill/1776>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (23 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cummings, Elijah E. [D-MD-7]	D · MD		Mar 29, 2017
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Mar 29, 2017
Rep. Welch, Peter [D-VT-At Large]	D · VT		Mar 29, 2017
Rep. Grijalva, Raúl M. [D-AZ-3]	D · AZ		Apr 5, 2017
Rep. Pocan, Mark [D-WI-2]	D · WI		Apr 5, 2017
Rep. Conyers, John, Jr. [D-MI-13]	D · MI		Apr 6, 2017
Rep. Peterson, Collin C. [D-MN-7]	D · MN		Apr 6, 2017
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Apr 25, 2017
Rep. Ellison, Keith [D-MN-5]	D · MN		Apr 25, 2017
Rep. Shea-Porter, Carol [D-NH-1]	D · NH		Apr 25, 2017
Rep. Rush, Bobby L. [D-IL-1]	D · IL		May 16, 2017
Rep. Nolan, Richard M. [D-MN-8]	D · MN		May 18, 2017
Rep. Pingree, Chellie [D-ME-1]	D · ME		May 18, 2017
Rep. Chu, Judy [D-CA-27]	D · CA		Jun 6, 2017
Rep. Cohen, Steve [D-TN-9]	D · TN		Jun 23, 2017
Rep. McCollum, Betty [D-MN-4]	D · MN		Jul 26, 2017
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Sep 6, 2017
Rep. DeFazio, Peter A. [D-OR-4]	D · OR		Oct 24, 2017
Rep. Ryan, Tim [D-OH-13]	D · OH		Oct 24, 2017
Rep. Visclosky, Peter J. [D-IN-1]	D · IN		Nov 1, 2017
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		May 21, 2018
Rep. Khanna, Ro [D-CA-17]	D · CA		Jul 25, 2018
Rep. Maloney, Sean Patrick [D-NY-18]	D · NY		Nov 27, 2018

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 31, 2017
Judiciary Committee	House	Referred To	Mar 29, 2017
Ways and Means Committee	House	Referred to	Apr 5, 2017

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
115 S 3411	Related bill	Sep 5, 2018: Read twice and referred to the Committee on Finance.
115 HR 6340	Related bill	Jul 11, 2018: Referred to the House Committee on Energy and Commerce.
115 S 2478	Related bill	Mar 1, 2018: Read twice and referred to the Committee on Finance.
115 S 2476	Related bill	Feb 28, 2018: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
115 S 1688	Related bill	Aug 1, 2017: Read twice and referred to the Committee on Finance.
115 S 771	Identical bill	Mar 29, 2017: Read twice and referred to the Committee on Finance.
115 HR 1245	Related bill	Mar 3, 2017: Referred to the Subcommittee on Health.
115 S 469	Related bill	Feb 28, 2017: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
115 S 348	Related bill	Feb 9, 2017: Read twice and referred to the Committee on Finance.
115 S 252	Related bill	Feb 1, 2017: Read twice and referred to the Committee on Finance.

This bill amends provisions of various laws relating to prescription-drug pricing and affordability. Specifically, the bill:

- expands reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance;
- adds reporting requirements for certain nonprofit patient-assistance programs;
- requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures;
- requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program;
- requires the GAO to report to Congress on such negotiations conducted by the CMS;
- requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices;
- establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices;
- establishes an excise tax on prescription drugs subject to price spikes;
- lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program;
- modifies provisions related to the importation of prescription drugs;
- requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program;
- establishes a prize fund for new and more effective treatments of bacterial infections;
- establishes a Center for Clinical Research within the National Institutes of Health;
- modifies provisions related to drug exclusivity;
- allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product;
- requires the Food and Drug Administration to establish a database of generic drugs; and
- modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.

Actions Timeline

- **Apr 5, 2017:** Referred to the Subcommittee on Health.
- **Mar 31, 2017:** Referred to the Subcommittee on Health.
- **Mar 29, 2017:** Introduced in House
- **Mar 29, 2017:** Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.